9 Schizophrenia Clinical Trials in Lemon Grove, CA (2026)

Q: How do I join a clinical trial in Lemon Grove?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Lemon Grove research site will contact you.

Recruiting Schizophrenia Studies in Lemon Grove

NCT05184335Recruiting

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg o...

Lemon Grove, CAPHASE3690 participantsReviva Pharmaceuticals

View Study Details

NCT07114874Recruiting

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia....

Lemon Grove, CAPHASE3600 participantsNeurocrine Biosciences

View Study Details

NCT07227818Recruiting

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with N...

Lemon Grove, CAPHASE3560 participantsNeurocrine Biosciences

View Study Details

NCT06894212Recruiting

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...

Lemon Grove, CAPHASE3522 participantsOtsuka Pharmaceutical Development & Commercialization, Inc.

View Study Details

NCT07459647Recruiting

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an ...

Lemon Grove, CAPHASE2500 participantsMapLight Therapeutics

View Study Details

NCT07363577Recruiting

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult pati...

Lemon Grove, CAPHASE3456 participantsLB Pharmaceuticals Inc.

View Study Details

NCT06961968Recruiting

Randomized Withdrawal Study in Patients With Schizophrenia

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia...

Lemon Grove, CAPHASE3400 participantsVanda Pharmaceuticals

View Study Details

NCT05304767Recruiting

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inade...

Lemon Grove, CAPHASE3280 participantsKaruna Therapeutics

View Study Details

NCT07191483Recruiting

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 ...

Lemon Grove, CAPHASE2150 participantsKynexis B.V.

View Study Details

About Schizophrenia Clinical Trials in Lemon Grove

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 9 schizophrenia clinical trials recruiting participants in Lemon Grove, CA. These studies are seeking a combined 4,158 participants. Research is being sponsored by Reviva Pharmaceuticals, Neurocrine Biosciences, Otsuka Pharmaceutical Development & Commercialization, Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Schizophrenia Clinical Trials in Lemon Grove — FAQ

Are there schizophrenia clinical trials in Lemon Grove?

Yes, there are 9 schizophrenia clinical trials currently recruiting in Lemon Grove, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Lemon Grove?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lemon Grove research site will contact you about next steps.

Are clinical trials in Lemon Grove free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lemon Grove studies also compensate for your time and travel.

What schizophrenia treatments are being tested?

The 9 active trials in Lemon Grove are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.

Data updated July 22, 2026 from ClinicalTrials.gov